AstraZeneca Flaunts Stand-Alone Prospects With $2.1B Deal
AstraZeneca PLC said Wednesday it would pay up to $2.1 billion for the rights to respiratory drugs developed by Almirall SA, showcasing its deal-making prowess and bright prospects as a stand-alone...To view the full article, register now.
Already a subscriber? Click here to view full article